EyePoint Announces Pricing of Public Offering
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Model output · Signal date 2026-10-13
Eyepoint, Inc. (EYPT) Stock Forecast Oct. 13, 2026
Analysis updated on Oct. 13, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
▲ Bullish
Exact rating locked
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
Top 35%
of 4004 stocks scored
Rank correlation · 90D
n/a
No per-ticker sample yet
Market Cap
$265M
small-cap · #14 of 25 peers
Summary
Eyepoint, Inc. (EYPT) stock forecast summary
Our AI ranks Eyepoint, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Eyepoint, Inc. is a small-cap company with a market capitalization of $265M. It ranks number 14 by market capitalization among the 25 Laboratory Analytical Instruments issuers in our coverage with a current forecast. Its Net Margin of -10998.7% is the lowest of the 20 peers that report one.
A per-ticker accuracy statistic for EYPT is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.6%, strong sell < -1.7% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, EYPT included.
Follow EYPT freePrice
EYPT price chart and AI forecast
Cross-section · 2026-10-14
How EYPT ranks among 4004 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals
Eyepoint, Inc. (EYPT) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Laboratory Analytical Instruments peers listed below that report each metric.
Valuation & Market
| Metric | EYPT | Rank |
|---|---|---|
| Market Cap | $265M | 14/25 |
| P/B Ratio | 1.59x | 17/23 |
| EPS | $-3.41 | – |
| Book Value/Share | $1.93 | – |
| Revenue/Share | $0.03 | – |
| FCF/Share | $-3.15 | – |
Profitability & Margins
| Metric | EYPT | Rank |
|---|---|---|
| ROE | -184.3% | 20/21 |
| ROA | -134.4% | 22/22 |
| ROIC | -170.2% | 21/21 |
| Operating Margin | -11369.3% | 21/21 |
| Net Margin | -10998.7% | 20/20 |
| EBT Margin | -10947.2% | 22/22 |
| Tax Rate | -0.0% | – |
Financial Health
| Metric | EYPT | Rank |
|---|---|---|
| Current Ratio | 4.50x | 9/25 |
| Quick Ratio | 4.46x | 6/24 |
| D/E Ratio | 0.37x | 16/24 |
| Financial Leverage | 1.37x | 16/24 |
| Interest Coverage | -52.3x | 17/21 |
| Working Capital | $147M | 14/25 |
Cash Flow
| Metric | EYPT | Rank |
|---|---|---|
| Operating Cash Flow | -$267M | 24/24 |
| Free Cash Flow | -$271M | 20/20 |
| Capital Spending | -$4M | 10/20 |
| FCF/Sales | -9730.2% | 19/19 |
| CapEx/Sales | 142.8% | 1/19 |
Operational Efficiency
| Metric | EYPT | Rank |
|---|---|---|
| Asset Turnover | 0.01x | 21/21 |
| Fixed Assets Turnover | 0.3x | 21/21 |
Income Statement
| Metric | EYPT | Rank |
|---|---|---|
| Total Revenue | $2M | 21/21 |
| Operating Income | -$316M | 21/21 |
| Net Income | -$306M | 21/22 |
| R&D Expense | $263M | 6/21 |
| SG&A Expense | $130M | 13/20 |
Dividend & Shareholder Information
| Metric | EYPT | Rank |
|---|---|---|
| Shares Outstanding | 86M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $189M | 82.7% of assets |
| Cash & Short-term Investments | $110M | 48.4% of assets |
| Inventory | $2M | 0.8% of assets |
| Total Liabilities | $62M | 27.1% of assets |
| Short-term Debt | $25M | 10.8% of assets |
Quarterly Financial Reports
EYPT quarterly financials and insider trading
Industry Peers · Laboratory Analytical Instruments
Eyepoint, Inc. (EYPT) industry peers
Companies classified under the same SEC industry code as Eyepoint, Inc. (Laboratory Analytical Instruments): 25 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| EYPT Eyepoint, Inc. | ▲ | $265M |
| A Agilent Technologies, Inc. | ▼ | $48.38B |
| WAT Waters Corp /De/ | ▲ | $42.17B |
| ILMN Illumina, Inc. | ▶ | $40.95B |
| MTD Mettler Toledo International Inc/ | ▼ | $32.02B |
| RVTY Revvity, Inc. | ▼ | $17.30B |
| AVTR Avantor, Inc. | ▶ | $10.62B |
| BIO Bio-Rad Laboratories, Inc. | ▼ | $9.73B |
| TXG 10x Genomics, Inc. | ▲ | $9.35B |
| BRKR Bruker Corp | ▲ | $8.56B |
| ALMR Alamar Biosciences, Inc. | ▶ | $1.63B |
| CTKB Cytek Biosciences, Inc. | ▲ | $695M |
| PACB Pacific Biosciences Of California, Inc. | ▲ | $637M |
| MASS 908 Devices Inc. | ▲ | $500M |
| NAUT Nautilus Biotechnology, Inc. | ▲ | $261M |
| BFNH Bioforce Nanosciences Holdings, Inc. | ▼ | $250M |
| QTRX Quanterix Corp | ▲ | $149M |
| SEER Seer, Inc. | ▶ | $117M |
| RPID Rapid Micro Biosystems, Inc. | ▲ | $44M |
| PRPO Precipio, Inc. | ▲ | $40M |
| HBIO Harvard Bioscience Inc | ▼ | $38M |
| BNGO Bionano Genomics, Inc. | ▲ | $16M |
| LCTC Lifeloc Technologies, Inc | ▲ | $11M |
| ASTC Astrotech Corp | ▶ | $11M |
| SCND Scientific Industries Inc | ▲ | $8M |
Where EYPT sits on the market map
Industrial Applications and Services · Laboratory Analytical Instruments
News
Eyepoint, Inc. (EYPT) stock news
EyePoint, Inc. (EYPT) Discusses LUGANO Top Line Data From Phase III Wet AMD Trial for DURAVYU Transcript
Ladies and gentlemen, thank you for standing by. Welcome to EyePoint LUGANO Top Line Data Readout. [Operator Instructions]. Please be advised that today's conference is being recorded. I would like ...
EyePoint, Inc. (EYPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Great. First, welcome to Jay Duker and George Elston from EyePoint Pharmaceuticals here at the 47th Annual Goldman Sachs Healthcare Conference. Welcome, gentlemen. For those in the audience and ...
FAQ
Eyepoint, Inc. (EYPT) stock forecast FAQ
What is the Eyepoint, Inc. (EYPT) stock forecast?
Our AI ranks Eyepoint, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Eyepoint, Inc. stock predictions?
A per-ticker accuracy statistic for EYPT is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Eyepoint, Inc. forecasts updated?
Eyepoint, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
Which companies are Eyepoint, Inc.'s industry peers?
25 issuers in our coverage, EYPT included, share the SEC industry code Laboratory Analytical Instruments. The largest are: Agilent Technologies, Inc. (A), Waters Corp /De/ (WAT), Illumina, Inc. (ILMN), Mettler Toledo International Inc/ (MTD), Revvity, Inc. (RVTY), Avantor, Inc. (AVTR).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.